Literature DB >> 15068800

Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.

Karthe Ponnuraj1, Yuanyuan Xu, Kevin Macon, Dwight Moore, John E Volanakis, Sthanam V L Narayana.   

Abstract

The C-terminal fragment, Bb, of factor B combines with C3b to form the pivotal C3-convertase, C3bBb, of alternative complement pathway. Bb consists of a von Willebrand factor type A (vWFA) domain that is structurally similar to the I domains of integrins and a serine protease (SP) domain that is in inactive conformation. The structure of the C3bBb complex would be important in deciphering the activation mechanism of the SP domain. However, C3bBb is labile and not amenable to X-ray diffraction studies. We engineered a disulfide bond in the vWFA domain of Bb homologous to that shown to lock I domains in active conformation. The crystal structures of Bb(C428-C435) and its inhibitor complexes reveal that the adoption of the "active" conformation by the vWFA domain is not sufficient to activate the C3-convertase catalytic apparatus and also provide insights into the possible mode of C3-convertase activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068800     DOI: 10.1016/s1097-2765(04)00160-1

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  37 in total

1.  Exposure of R169 controls protein C activation and autoactivation.

Authors:  Nicola Pozzi; Sergio Barranco-Medina; Zhiwei Chen; Enrico Di Cera
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

3.  The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  J Mol Biol       Date:  2006-12-19       Impact factor: 5.469

Review 4.  Complement and the multifaceted functions of VWA and integrin I domains.

Authors:  Timothy A Springer
Journal:  Structure       Date:  2006-11       Impact factor: 5.006

5.  Crystal structure of prethrombin-1.

Authors:  Zhiwei Chen; Leslie A Pelc; Enrico Di Cera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

6.  Stabilization of the E* form turns thrombin into an anticoagulant.

Authors:  Alaji Bah; Christopher J Carrell; Zhiwei Chen; Prafull S Gandhi; Enrico Di Cera
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

7.  The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

8.  3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.

Authors:  Eva Torreira; Agustín Tortajada; Tamara Montes; Santiago Rodríguez de Córdoba; Oscar Llorca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-09       Impact factor: 11.205

9.  Structure of Streptococcus agalactiae tip pilin GBS104: a model for GBS pili assembly and host interactions.

Authors:  Vengadesan Krishnan; Prabhat Dwivedi; Brandon J Kim; Alexandra Samal; Kevin Macon; Xin Ma; Arunima Mishra; Kelly S Doran; Hung Ton-That; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-05-15

10.  FACIN, a Double-Edged Sword of the Emerging Periodontal Pathogen Filifactor alocis: A Metabolic Enzyme Moonlighting as a Complement Inhibitor.

Authors:  Monika Jusko; Beata Miedziak; David Ermert; Michal Magda; Ben C King; Ewa Bielecka; Kristian Riesbeck; Sigrun Eick; Jan Potempa; Anna M Blom
Journal:  J Immunol       Date:  2016-09-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.